Showing results (211-220 of 297) with videos related to

Sort By:
Pageof 30
Blood|July 13, 2023
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemiaJayastu Senapati, Samuel Urrutia, Sanam Loghavi, et al.
British Journal of Haematology|August 23, 2023
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemiaGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Ziyi Li, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
IL-1β-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromesVera Adema, Irene Ganan-Gomez, Feiyang Ma, et al.
Blood|November 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AMLWarren Fiskus, Christopher P Mill, Prithviraj Bose, et al.
Blood Advances|April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimensCurtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.
Haematologica|May 2, 2024
Outcomes and genetic dynamics of acute myeloid leukemia at first relapseAlex Bataller, Hagop Kantarjian, Alexandre Bazinet, et al.
Blood Cancer Journal|May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AMLMusa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
The Lancet. Haematology|April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort studyCurtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With OlutasidenibKelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
American Journal of Hematology|September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remissionNicholas J Short, Walid Macaron, Tapan Kadia, et al.
Pageof 30